Prot #NU 13S02: Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

StatusActive
Effective start/end date2/28/142/28/22

Funding

  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #NU 13S02)